At the news
? NEUTRALIMPACT 3/10 424B5 filed Nov 9, 2026 at 08:24 ET
IIPR filed a prospectus supplement to its existing $500M ATM equity shelf program, updating the mix of securities (common, Series A preferred, Series B preferred) and the aggregate amount remaining available for sale to approximately $336.9M. The filing follows a Q3 2026 earnings beat (AFFO $1.96 vs $1.65 consensus) reported 7 days ago, and proceeds are earmarked for life science investments, IQHQ mezzanine loan funding, debt repayment and working capital. The ATM capacity itself is not a priced offering, so the immediate dilutive impact is contingent on future sales.
- IIPR filed a 424B5 prospectus supplement updating its $500M ATM equity shelf program for common stock, Series A and Series B preferred stock.
- Approximately $163.1M of the $500M shelf has been sold under prior supplements, leaving $336.9M available for future at-the-market sales.
- The filing amends and replaces the prior prospectus supplement dated February 26, 2025, as previously supplemented.
- Proceeds are intended to fund investments (real estate, life science, joint ventures), the IQHQ Alewife Mezzanine Loan ($134M unfunded as of Sep 30, 2026), repay revolving credit facilities ($87.5M and $100M outstanding), and for working capital.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access